Novo Nordisk Taps Ascendis For Development Of A Once-Monthly GLP-1 Agonist

Extends TransCon Platform Into Metabolic Diseases

 
• By Mandy Jackson
  
Once-monthly injections would have a convenience advantage over available once-weekly obesity drugs (Shutterstock)

More from Deals

More from Scrip